Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 1720-1726

  Marcelin, Anne Geneviève ^a   Cohen Codar, Isabelle ^c   King, Martin S ^b   Colson, Philippe ^b   Guillevic, Emmanuel ^c   Descamps, Diane ^b   Lamotte, Claire ^d   Schneider, Véronique ^b   Ritter, Jacques ^b   Segondy, Michel ^b   Peigue Lafeuille, Hélène ^b   Morand Joubert, Laurence ^b   Schmuck, Anne ^b   Ruffault, Annick ^b   Palmer, Pierre ^b   Chaix, Marie Laure ^b   Mackiewicz, Vincent ^b   Brodard, Véronique ^b   Izopet, Jacques ^b   Cottalorda, Jacqueline ^b   Kohli, Evelyne ^b   Chauvin, Jean Pierre ^c   Kempf, Dale J ^b   Peytavin, Gilles ^d   Calvez, Vincent ^a   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Department of Virology ^*

^c Abbott   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GENETIC RESISTANCE; GENOTYPIC INHIBITORY QUOTIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAMETER; PREDICTION; PRIORITY JOURNAL; TECHNIQUE; VIROLOGY;

ADULT; AGED; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PYRIMIDINONES; RITONAVIR; RNA, VIRAL;

EID: 20944446492     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.1720-1726.2005     Document Type: Article

References (19)

1. Benson, C. A., S. G. Decks, S. C. Brun, R. M. Gulick, J. J. Eron, H. A. Kessler, R. L. Murphy, C. Hicks, M. King, D. Wheeler, J. Feinberg, R. Stryker, P. E. Sax, S. Riddler, M. Thompson, K. Real, A. Hsu, D. Kempf, A. J. Japour, and E. Sun. 2002. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J. Infect. Dis. 185:599-607.
2. Boffito, M., I. Arnaudo, R. Raiteri, S. Bonora, A. Sinicco, A. Di Garbo, H. E. Reynolds, P. G. Hoggard, D. J. Back, and G. Di Perri. 2002. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 16:2081-2083.
3. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
4. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. Phillips, M. Ait-Khaled, J. Baxter, P. Clevenbergh, S. Hammer, R. Harrigan, D. Katzenstein, R. Lanier, M. Miller, M. Para, S. Yerly, A. Zolopa, J. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: reanalysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41-48.
5. Durant, J., P. Clevenbergh, R. Garraffo, P. Halfon, S. Icard, P. Del Giudice, N. Montagne, J. M. Schapiro, and P. Dellamonica. 2000. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 14:1333-1339.
6. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokmetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 47:350-359.
7. Jung, M., H. Agut, D. Candotti, D. Ingrand, C. Katlama, and J. Huraux. 1992. Suceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J. Acquir. Immune Defic. Syndr. 5:359-364.
8. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
9. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
10. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
11. Marcelin, A. G., C. Lamotte, C. Delaugerre, N. Ktorza, H. Ait Mohand, R. Cacace, M. Bonmarchand, M. Wirden, A. Simon, P. Bossi, F. Bricaire, D. Costagliola, C. Katlama, G. Peytavin, and V. Calvez. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 47:594-600.
12. Marsh, K. C., E. Eiden, and E. McDonald. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase hieh-performance liquid chromatography. J. Chromatoer. B Biomed. Sci. Appl. 704:307-313.
13. Masquelier, B., D. Breilh, D. Neau, S. Lawson-Ayayi, V. Lavignolle, J. M. Ragnaud, M. Dupon, P. Morlat, F. Dabis, and H. Fleury. 2002. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46: 2926-2932.
14. Murphy, R. L., S. Brun, C. Hicks, J. J. Eron, R. Gulick, M. King, A. C. White, Jr., C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-I infection: 48-week results. AIDS 15:Fl-9.
15. Nyhuis, M., C. A. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
16. Parkin, N. T., C. Chappey, and C. J. Petropoulos. 2003. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17:955-961.
17. Shulman, N., A. Zolopa, D. Havlir, A. Hsu, C. Renz, S. Boller, P. Jiang, R. Rode, J. Gallant, E. Race, D. Kempf, and E. Sun. 2002. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in HIV-infected patients with with ongoing viremia. Antimicrob. Agents Chemother. 46:3907-3916.
18. Torti, C., E. Quiros-Roldan, W. Keulen, L. Scudeller, S. Lo Caputo, C. Boucher, F. Castelli, F. Mazzotta, P. Pierotti, A. M. Been-Tiktak, G. Buccoliero, M. De Gennaro, G. Carosi, and C. Tinelli. 2003. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J. Infect. Dis. 188:194-201.
19. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.